Q-omics provides the consensus-scored MORF4L1 profile across patient tissues and cancer cell-line models. MORF4L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MORF4L1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MORF4L1 protein abundance shows 21,070 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where MORF4L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MORF4L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MORF4L1 survival associations across molecular data types. MORF4L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MORF4L1 RNA expression–survival associations across cancer types. High MORF4L1 expression shows unfavorable associations in HNSC, ACC, UVM and BLCA, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MORF4L1 RNA expression.
This table summarizes MORF4L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MORF4L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MORF4L1 shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher MORF4L1 RNA expression in tumor versus normal tissue (log2 FC = +0.970, t-test p < 0.001).
This table shows molecular features associated with MORF4L1 in patient tissues and cancer cell lines. In patient samples, MORF4L1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MORF4L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
